Previous Close | 14.90 |
Open | 14.90 |
Bid | 15.90 x N/A |
Ask | 16.00 x N/A |
Day's Range | 14.90 - 14.90 |
52 Week Range | 9.85 - 24.20 |
Volume | |
Avg. Volume | 11 |
Market Cap | 1.423B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Key Insights Significant control over Gyre Therapeutics by public companies implies that the general public has more...
Transformational Year with Strategic Shifts and Clinical Advances
Data readout from Phase 3 clinical trial in the People's Republic of China (“PRC”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025 Appointed Dr. Han Ying as Chief Executive Officer Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreeme